Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:TRML

Tourmaline Bio Q3 2024 Earnings Report

Tourmaline Bio logo
ProfileEarnings HistoryForecast

Tourmaline Bio EPS Results

Actual EPS
-$0.78
Consensus EPS
-$0.84
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Tourmaline Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tourmaline Bio Announcement Details

Quarter
Q3 2024
Date
11/7/2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
8:30AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Tourmaline Bio's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Tourmaline Bio Earnings Headlines

Tourmaline Bio acquisition completed by Novartis
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/tourmaline-bio-acquisition-completed-by-novartis/ar-AA1PmVFi
Novartis announces expiration of Tourmaline Bio tender offer
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/novartis-announces-expiration-of-tourmaline-bio-tender-offer/ar-AA1PlhGR
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
 |  Brownstone Research (Ad)
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
October 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251006398102/en/tourmaline-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-tourmaline-bio-inc.---trml/
Tourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90
September 30, 2025  |  msn.comhttps://www.msn.com/en-us/general/general/tourmaline-bio-trml-price-target-decreased-by-14-70-to-48-90/ar-AA1NA13M
Novartis announces commencement of tender offer to acquire Tourmaline Bio
September 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/29/3157623/0/en/novartis-announces-commencement-of-tender-offer-to-acquire-tourmaline-bio.html
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio (NASDAQ:TRML) operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

View Tourmaline Bio Profile
Earnings Tools